Celularity Inc.
- CELU
- NASDAQ
- Biotechnology
- Allogeneic Cell Therapy
- Placental-Derived Treatments
$1.16
Today −7.20%Quote Oct 19, 2026, 08:00 PM UTC
−11.45%over the last month
Max drawdown −32.2%From 1-month high −32.2%3 months +43.2%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Celularity
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases.
Where the money comes from
Q1 2026 revenue $3.8M
- License Royalty and Other$1.7M45.0%
- Service$1.3M32.5%
- Product$866,00022.5%
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
115
Founded
2016
Market value
$37.6M
Quote Oct 19
Analyst target
$3.00
+158.6% from here
Floor
$1.14
1.7% below price
Resistance
$1.19
2.7% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about CELUPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free